Maher Masoud Biography and Net Worth

CEO of MaxCyte

Mr. Masoud was named President and Chief Executive Officer of MaxCyte in January of 2024. He brings more than 25 years of experience in the biopharmaceutical industry, including 17 years as an attorney and general counsel, to his new role at MaxCyte. Mr. Masoud has most recently served as Executive Vice President, Head of Global Business Development, and Chief Counsel at MaxCyte. During his tenure, MaxCyte’s strategic platform license (SPL) partnerships grew to include 29 partners (as of September 2024).

Mr. Masoud started his biopharmaceutical career as a research associate with Glen Research, a Maravai company, before joining Human Genome Sciences as Director and Corporate Counsel, overseeing legal activities for the company’s global clinical trials, until its acquisition by GlaxoSmithKline. Prior to joining MaxCyte, he oversaw the operations of six business subsidiaries at Wellstat, a life science holding company. During his tenure at Human Genome Sciences and Wellstat, Mr. Masoud supported the launch of three FDA approved therapies, Benlysta^®, Vistogard^® and Xuriden^®.

Mr. Masoud earned his Juris Doctor degree from Michigan State University College of Law after completing his Bachelor of Science degree in cell and molecular biology genetics at the University of Maryland.

What is Maher Masoud's net worth?: The estimated net worth of Maher Masoud is at least $276.50 thousand as of August 13th, 2025. Mr. Masoud owns 175,000 shares of MaxCyte stock worth more than $276,500 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Masoud may own. Additionally, Mr. Masoud receives an annual salary of $650,980.00 as CEO at MaxCyte. Learn More about Maher Masoud's net worth.
How old is Maher Masoud?: Mr. Masoud is currently 49 years old. There are 6 older executives and no younger executives at MaxCyte. The oldest executive at MaxCyte is Dr. J. Stark Thompson Ph.D., Consultant, who is 82 years old. Learn More on Maher Masoud's age.
What is Maher Masoud's salary?: As the CEO of MaxCyte, Inc., Mr. Masoud earns $650,980.00 per year. The highest earning executive at MaxCyte is Mr. Douglas Arthur Doerfler, Founder, who commands a salary of $2,340,000.00 per year. Learn More on Maher Masoud's salary.
How do I contact Maher Masoud?: The corporate mailing address for Mr. Masoud and other MaxCyte executives is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. MaxCyte can also be reached via phone at 301-944-1700 and via email at [email protected]. Learn More on Maher Masoud's contact information.
Has Maher Masoud been buying or selling shares of MaxCyte?: Maher Masoud has not been actively trading shares of MaxCyte within the last three months. Most recently, on Wednesday, August 13th, Maher Masoud bought 75,000 shares of MaxCyte stock. The stock was acquired at an average cost of $1.37 per share, with a total value of $102,750.00. Following the completion of the transaction, the chief executive officer now directly owns 175,000 shares of the company's stock, valued at $239,750. Learn More on Maher Masoud's trading history.
Who are MaxCyte's active insiders?: MaxCyte's insider roster includes Douglas Doerfler (Founder), Douglas Doerfler (Founder), Stanley Erck (Director), John Johnston (Director), Maher Masoud (CEO), David Sandoval (Senior Vice President and General Counsel), Ali Soleymannezhad (Insider), and Douglas Swirsky (CFO). Learn More on MaxCyte's active insiders.
Are insiders buying or selling shares of MaxCyte?: In the last year, MaxCyte insiders bought shares 5 times. They purchased a total of 355,000 shares worth more than $479,950.00. In the last year, insiders at the sold shares 7 times. They sold a total of 29,653 shares worth more than $95,594.74. The most recent insider tranaction occured on August, 13th when CFO Douglas J Swirsky bought 50,000 shares worth more than $64,500.00. Insiders at MaxCyte own 3.3% of the company. Learn More about insider trades at MaxCyte.
Information on this page was last updated on 8/13/2025.

Maher Masoud Insider Trading History at MaxCyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/13/2025	Buy	75,000	$1.37	$102,750.00	175,000
6/10/2024	Buy	70,443	$4.90	$345,170.70	100,000
6/7/2024	Buy	29,557	$4.87	$143,942.59	29,557

Maher Masoud Buying and Selling Activity at MaxCyte

MaxCyte Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Today's Range

Now: $1.58

$1.50

$1.62

50 Day Range

MA: $1.62

$1.44

$1.83

2 Week Range

Now: $1.58

$1.26

$5.20

Volume

577,871 shs

Average Volume

856,912 shs

Market Capitalization

$168.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Maher Masoud Biography and Net Worth

What is Maher Masoud's net worth?

How old is Maher Masoud?

What is Maher Masoud's salary?

How do I contact Maher Masoud?

Has Maher Masoud been buying or selling shares of MaxCyte?

Who are MaxCyte's active insiders?

Are insiders buying or selling shares of MaxCyte?